The clinical spectrum and pathophysiology of skeletal complications in lysosomal storage disorders
- 1 March 2015
- journal article
- review article
- Published by Elsevier BV in Best Practice & Research Clinical Endocrinology & Metabolism
- Vol. 29 (2), 219-235
- https://doi.org/10.1016/j.beem.2014.08.010
Abstract
No abstract availableKeywords
This publication has 60 references indexed in Scilit:
- Osteopenia in Gaucher disease develops early in life: Response to imiglucerase enzyme therapy in children, adolescents and adultsBlood Cells, Molecules, and Diseases, 2011
- Glucocerebrosidase gene-deficient mouse recapitulates Gaucher disease displaying cellular and molecular dysregulation beyond the macrophageProceedings of the National Academy of Sciences of the United States of America, 2010
- A phase 2 study of eliglustat tartrate (Genz-112638), an oral substrate reduction therapy for Gaucher disease type 1Blood, 2010
- Involvement of the Toll-like receptor 4 pathway and use of TNF-α antagonists for treatment of the mucopolysaccharidosesProceedings of the National Academy of Sciences of the United States of America, 2009
- Altered lumbar spine structure, biochemistry, and biomechanical properties in a canine model of mucopolysaccharidosis type VIIJournal of Orthopaedic Research, 2009
- Characterization of Gaucher disease bone marrow mesenchymal stromal cells reveals an altered inflammatory secretomeBlood, 2009
- Mechanism of shortened bones in mucopolysaccharidosis VIIMolecular Genetics and Metabolism, 2009
- Gaucher disease: Resetting the clinical and scientific agendaAmerican Journal of Hematology, 2009
- Radiographic evaluation of bones and joints in mucopolysaccharidosis I and VII dogs after neonatal gene therapyMolecular Genetics and Metabolism, 2008
- Improvement of bone disease by imiglucerase (Cerezyme) therapy in patients with skeletal manifestations of type 1 Gaucher disease: results of a 48‐month longitudinal cohort studyClinical Genetics, 2008